ABSTRACT

Ace Inhibitors

B

C

E

F

L

P

Q

R

T

Z

=

SKIN

Anaphylaxis

[1]

[1]

[1]

Angioedema

[8]

[45] (15%)

[73]

[3]

[41] (70%)

[6]

[9]

[11]

[3]

[1]

✓✓

Bullous dermatitis

[1]

[1]

Bullous pemphigoid

[2]

[2]

Dermatitis

[3]

[1]

[1]

Diaphoresis

[1]

[1]

[3]

[2]

DRESS syndrome

[2]

[1]

Edema

[1]

[4]

[1]

Erythema

[1]

[1]

[1]

Erythema multiforme

Erythroderma

[2]

[1]

[1]

Exanthems

[1]

[19] (10%)

[9]

[4]

[1]

[1]

Exfoliative dermatitis

[4]

[2]

Facial edema

[1]

[1]

Jaundice

[1]

[1]

Kaposi’s sarcoma

[2]

[2]

[1]

Lichen planus pemphigoides

[2]

[3]

Lichenoid eruption

[12]

[2]

[2]

Linear IgA

[1]

[5]

Lupus erythematosus

[8]

[2]

[1]

Mycosis fungoides

[2]

[1]

Palmar–plantar pustulosis

[1]

[1]

Pemphigus

[1]

[23]

[10]

[1]

[1]

[1]

Pemphigus foliaceus

[1]

[2]

[2]

[1]

[2]

[1]

[1]

[1]

[1]

Peripheral edema

[3]

[2]

[1]

[3]

[3]

Photosensitivity

[3]

[2]

[2]

[2]

Pityriasis rosea

[6]

[2]

Pruritus

[1]

[8] (10%)

[3]

[1]

(<10%)

[7]

[3]

Pseudolymphoma

[2]

[1]

[1]

Psoriasis

[8]

[3]

[1]

[1]

Purpura

[1]

[1]

[2]

Rash

[1]

[11] (4–7%)

[5]

[1]

[6]

[1] (<10%)

[5]

[4]

✓✓

Stevens–Johnson syndrome

[1]

[1]

Toxic epidermal necrolysis

[3]

Urticaria

[1]

[9] (7%)

[5]

[2]

Vasculitis

[7]

[2]

[1]

[1]

Xerosis

[1]

HAIR

Alopecia

[4]

[1]

[1]

(<10%)

NAILS

Nail dystrophy

[2]

[1]

MUCOSAL

Burning mouth syndrome

[1]

[1]

[1]

Glossitis

[3]

Glossopyrosis

[1]

[1]

Oral burn

[1]

[1]

Oral ulceration

[4]

[2]

Sialorrhea

[1]

Tongue edema

[2]

[2]

[2]

Xerostomia

[1]

B Benazepril; C Captopril; E Enalapril; F Fosinopril; L Lisinopril; P Perindopril; Q Quinapril; R Ramipril; T Trandolapril; Z Zofenopril These tables concentrate on skin, hair, nails and mucosal reactions.

reaction noted (package inserts)

number of published reports of a reaction

(8%) highest incidence that has ever been noted or reported

? 20 reports or over or an incidence of 20% or over recorded for this reaction for a minority of drugs in the class

at least half the drugs in the class selection have this reaction noted or reported

all drugs in the class selection have this reaction noted or reported

Note: reactions noted or reported for only one drug in a class selection have been excluded Antiarrhythmics

A

Di

Dr

F

I

L

Pn

Pf

Pr

Q

S

=

SKIN

Acneform eruption

[2]

[2]

AGEP

[1]

[2]

Anaphylaxis

[2]

[1]

[7]

[1]

Angioedema

[2]

[3]

[1]

[1]

[2]

Bullous dermatitis

[1]

[1]

Dermatitis

(5%)

[27]

[1] (6%)

[2]

[4]

Diaphoresis

[2]

[1]

[1]

Eczema

(5%)

[3]

[2]

Edema

(<10%)

[2]

(5%)

Erythema

(5%)

[3]

[1]

[1]

Erythema multiforme

[1]

[2]

[1]

[1]

Erythema nodosum

[2]

[1]

[1]

Exanthems

[5]

[1] (<5%)

[1]

[1]

[2]

[5] (8%)

[1]

[4]

[6] (17%)

Exfoliative dermatitis

[1]

[2]

[1]

[5]

Fixed eruption

[1]

[2]

[1]

[2]

Hypersensitivity

[1]

[1]

[9]

[2]

[1]

Leukocytoclastic vasculitis

[1]

[1]

Lichen planus

[1]

[7]

Lichenoid eruption

[3]

[6]

[1]

Lupus erythematosus

[5] (5%)

[3]

[1]

[175] (15–20%)

[3]

[2]

[35]

Necrosis

[1]

[3]

Photosensitivity

[41] (10–75%)

[1]

[1]

[1]

[21]

Phototoxicity

[3]

[1]

[1]

[1]

Pigmentation

[68] (<10%)

[1]

[3]

?

Pruritus

[2] (<5%)

(5%)

[3]

[1]

[3]

(<10%)

Psoriasis

[2]

[2]

[2]

[20]

[5]

[3]

Purpura

[1]

[1]

[1]

[3]

[1]

[13]

Rash

[1]

[7](5%)

[2](<10%)

(<10%)

Raynaud’s phenomenon

[3] (59%)

Sjögren’s syndrome

[1]

[1]

Stevens–Johnson syndrome

[1]

[2]

Toxic epidermal necrolysis

[2]

[1]

[1]

[2]

Toxicity

[4]

[1]

[1]

[3]

[1]

Urticaria

[1]

[5]

[1] (<5%)

[1]

[3]

[1]

Vasculitis

[5]

[5]

[5]

[1]

HAIR

Alopecia

[5]

[6]

[1]

MUCOSA

Loral lesions

[1] (40%)

[1]

?

Oral mucosal eruption

[1]

[2]

Oral ulceration

[1]

[1]

[1]

Sialorrhea

(<10%)

[1]

Xerostomia

[2] (40%)

[1]

?

A Amiodarone; Di Disopyramide; Dr Dronedarone; F Flecainide; I Ibutilide; L Lidocaine; Pn Procainamide; Pf Propafenone; Pr Propranolol; Q Quinidine; S Sotalol Antibiotics, Macrolide

A

C

E

=

SKIN

Anaphylaxis

[2]

[2]

[2]

✓✓

Angioedema

[1]

[1]

[1]

✓✓

Dermatitis

[1]

[4]

Exanthems

[3]

[1]

[4] (<5%)

✓✓

Fixed eruption

[3]

[6]

Hypersensitivity

[3]

[3]

[3] (<10%)

✓✓

Jarisch–Herxheimer reaction

[2]

[1]

Pruritus

[3]

[1]

Pustules

[1]

[1]

Rash

[6] (2–10%)

[2]

[3]

✓✓

SDRIFE

[1]

[2]

Stevens–Johnson syndrome

[6]

[1]

[7]

✓✓

Toxic epidermal necrolysis

[4]

[7]

Toxicity

[1]

[1]

Urticaria

[2]

[1]

[4]

✓✓

Vasculitis

[1]

[3]

[1]

✓✓

HAIR

Alopecia

[1]

[1]

MUCOSAL

Gingival hyperplasia/hypertrophy

[1]

[1]

A Azithromycin; C Clarithromycin; E Erythromycin Anticonvulsants

B

C

G

La

Le

O

Phb

Phy

Ti

To

V

Z

=

SKIN

Acne keloid

[1]

[2]

Acneform eruption

[1]

[1]

[1]

[8]

AGEP

[5]

[1]

[1]

[5]

Angioedema

[5]

[1](<10%)

[2]

Anticonvulsant hypersensitivity syndrome

[19]

[2]

[17]

[1]

[10]

[10]

[6]

Bullae

[1]

[1]

Bullous dermatitis

[4]

[1]

[5]

[1]

[1]

Bullous pemphigoid

[1]

[1]

Dermatitis

[7]

[1]

Diaphoresis

(<10%)

[1]

[1]

DRESS syndrome

[46](77%)

[14](11%)

[7]

[6]

[12](6%)

[28](68%)

[7]

[3]

Ecchymoses

(<6%)

[4](<5%)

Eczema

[2]

Edema

[5]

[1]

[1]

[2]

Epidermolysis bullosa

[1]

[1]

Erythema

[1]

[1](~10%)

[2]

Erythema multiforme

[16]

[4]

[2]

[7]

[11]

[3]

Erythroderma

[12]

[1]

[2](16%)

[8](6%)

[3]

Exanthems

[35](17%)

[2]

[18](20%)

[1]

[4]

[13](70%)

[22](71%)

[1]

[3](14%)

Exfoliative dermatitis

[24]

[1]

[6]

[15]

?

Facial edema

[2]

[1]

Fixed eruption

[10]

[1]

[1]

[9]

[5]

[2]

[1]

Furunculosis

(<5%)

Hand–foot syndrome

[1]

[1]

Hot flashes

[1]

(<10%)

(<10%)

Hyperhidrosis

[1]

Hypersensitivity

[69]

[1]

[28] (<10%)

[6]

[12]

[46] (23%)

[5]

[4]

Lichen planus

[2]

[1]

Lichenoid eruption

[7]

[1]

Linear IgA

[1]

[8]

Lupus erythematosus

[35]

[4]

[2]

[19]

[5]

[1]

Lymphadenopathy

[1]

Lymphoma

[2]

[6]

Lymphoproliferative disease

[5]

[1]

Mycosis fungoides

[3]

[1]

[1]

[7]

Oligohydrosis

[1]

[8]

Pemphigus

[3]

[1]

[2]

Peripheral edema

[1]

[11] (8%)

[1]

[1]

(<5%)

Petechiae

[1]

[1](<5%)

Photosensitivity

[9]

[2]

[1]

[1]

[1]

Pigmentation

[1]

[4]

Pruritus

[7]

[1]

[1]

[1]

[1]

[5]

[3]

[1]

[1] (2–6%)

Pseudolymphoma

[17]

[1]

[1]

[31]

[2]

?

Psoriasis

[1]

[1]

Purpura

[8]

[1]

[1]

[2]

[4]

[2]

Pustules

[5]

[1]

[3]

Rash

[29] (12%)

[2]

[49] (10–20%)

[4]

[10] (9%)

[4]

[12] (<10%)

[2] (5%)

[3] (6%)

[7] (10%)

[6] (7%)

Scleroderma

[1]

[1]

Serum sickness

[1]

[2]

Sjögren’s syndrome

[1]

[1]

[1]

[1]

Stevens–Johnson syndrome

[95] (68%)

[2]

[45] (30%)

[3]

[7]

[20] (15%)

[56] (68%)

[10]

[3]

Toxic epidermal necrolysis

[86] (68%)

[48] (13%)

[2]

[4]

[26] (13%)

[63] (68%)

[7]

[1]

Toxicity

[2]

[1]

[1]

Toxicoderma

[1]

[1]

Urticaria

[14] (7%)

[1]

[2]

[1]

[5]

[1]

[1]

Vasculitis

[7]

[1]

[1]

[1]

[11]

[3]

Vesiculobullous eruption

Xerosis

[1]

[1]

HAIR

Alopecia

[7] (~6%)

[2]

[1]

[3]

[2]

[20] (<10%)

Hirsutism

[1] (25%)

[8] (13%)

[2] (60%)

Poliosis

[1]

[1]

NAILS

Nail changes

[2]

Nail hypoplasia

[1]

[2]

[3]

Nail pigmentation

[1]

[1]

MUCOSAL

Epistaxis

Gingival hyperplasia/hypertrophy

[3] (16%)

[56] (16–94%)

[1]

[7] (42%)

Gingivitis

Glossitis

(<5%)

Halitosis

[1]

Mucocutaneous eruption

[4]

[2]

Mucocutaneous lymph node syndrome

[2]

[1]

Oral ulceration

[2]

[1]

[1]

[1]

Rectal hemorrhage

Sialorrhea

[1] (4–5%)

Stomatitis

(<5%)

Ulcerative stomatitis

Xerostomia

[1] (5%)

(6%)

[1]

[1]

[5] (16%)

[2] (<5%)

B Brivaracetam; C Carbamazepine; G Gabapentin; La Lamotrigine; Le Levetiracetam; O Oxcarbazepine; Phb Phenobarbital; Phy Phenytoin; Ti Tiagabine; To Topiramate; V Valproic Acid; Z Zonisamide Antidepressants, Tricyclic

Ami

Amo

C

I

N

T

=

SKIN

Angioedema

[1]

[1]

Bullous dermatitis

[1]

[1]

Dermatitis

[1]

[1]

Diaphoresis

[1](<10%)

(<10%)

[2] (43%)

[8] (25%)

(<10%)

[1] (<10%)

✓✓

DRESS syndrome

[2]

[1]

Edema

[1]

(<10%)

[1]

Exanthems

[2]

[6](6%)

Fixed eruption

[1]

[1]

Hypersensitivity

[1]

[2]

Lichen planus

[1]

[1]

Lupus erythematosus

[1]

[1]

Photosensitivity

[3]

[3]

[3]

[2]

✓✓

Pigmentation

[4]

[1]

[13]

Pruritus

[3]

[1]

[1] (6%)

[6]

Purpura

[2]

[3]

Rash

(<10%)

(8%)

Urticaria

[1]

[6]

Vasculitis

[1]

[1]

[1]

HAIR

Alopecia

[1]

[2]

✓✓

Alopecia areata

[1]

[1]

MUCOSAL

Stomatitis

[1]

[2]

Xerostomia

[15] (79%)

[1] (14%)

[6] (84%)

[16] (21%)

[9]

[2]

✓✓

Ami Amitriptyline; Amo Amoxapine; C Clomipramine; I Imipramine; N Nortriptyline; T Trimipramine Antihistamines (HI)

Ce

Chl

Des

Dy

Fex

H

Lev

Lor

O

P

=

SKIN

AGEP

[1]

[1]

[1]

[3]

Anaphylaxis

[2]

[1]

[4]

[2]

[1]

Angioedema

(<10%)

[1]

[3]

[1]

Bullous dermatitis

Dermatitis

[4] (<10%)

[4]

[1]

[1]

[3]

Desquamation

[1]

[1]

Diaphoresis

Eczema

[2]

[1]

Edema

Erythema multiforme

[2]

[2]

Exanthems

[1]

[1]

[3]

[1]

Fixed eruption

[6]

[4]

[3]

[3]

[3]

[1]

[1]

Hypersensitivity

[1]

[1]

Palmar erythema

[1]

[1]

Photosensitivity

(<10%)

[3]

[12]

Phototoxicity

[1]

[1]

[1]

Pruritus

[1]

[1]

[2]

[1]

Purpura

[1]

[1]

[2]

Rash

[1]

[1]

Toxic epidermal necrolysis

[3]

[2]

Toxicity

[2]

[1]

Urticaria

[8]

[1]

[3]

[3]

[1]

[4]

[3]

Xerosis

HAIR

Alopecia

MUCOSAL

Oral ulceration

[1]

[1]

Sialorrhea

Stomatitis

Xerostomia

[2](6%)

(<10%)

[3]

[1](<10%)

[2](12%)

[9]

[2](<10%)

Ce Cetirizine; Chl Chlorpheniramine; Des Desloratadine; Dy Diphenhydramine; Fex Fexofenadine; H Hydroxyzine; Lev Levocetirizine; Lor Loratadine; O Olopatadine; P Promethazine Antimalarials

Amo

A/L

Art

A/P

C

H

M

P

Quc

Qud

Qun

S

=

SKIN

Acneform eruption

[2]

[2]

AGEP

[1]

[1]

[22] (25%)

[1]

[2]

?

Anaphylaxis

[1]

[2]

Angioedema

[1]

[1]

[2]

[1]

Bullous dermatitis

[2]

[2]

[1]

Dermatitis

[1]

[2]

[1]

[4]

[6]

DRESS syndrome

[2]

[2]

[1]

Erythema

[2]

[1]

[1]

Erythema annulare centrifugum

[2]

[3]

Erythema multiforme

[2]

[1]

[4]

[1]

[2]

[3]

Erythema nodosum

[1]

[1]

Erythroderma

[3]

[2]

Exanthems

[1]

[3] (<5%)

[4] (<5%)

[1] (30%)

[3]

[3] (80%)

[6] (17%)

[3] (<5%)

[1]

Exfoliative dermatitis

[4]

[3]

[1]

[2]

[3] (8%)

[5]

[2]

[3]

Fixed eruption

[1]

[3]

[3]

[2]

[12]

[2]

Hypersensitivity

[1]

[1]

[1]

[1]

Lichen planus

[1]

[7]

[3]

Lichenoid eruption

[6]

[4]

[2]

[6] (12%)

[6]

[3]

Livedo reticularis

[6]

[3]

Lupus erythematosus

[35]

[1]

?

Lymphoproliferative disease

[1]

[1]

[1]

Ochronosis

[2]

[1]

Pemphigus

[1]

[1]

Photosensitivity

[8]

[6]

[3]

[1]

[21]

[19]

[2]

Phototoxicity

[1]

[1]

[3]

[1]

Pigmentation

[15]

[17](<10%)

[5]

[9]

[3]

[6]

Pruritus

[3]

[2]

[3]

(<10%)

[36] (47%)

[12] (47%)

[2] (4–10%)

[2]

[3]

[1]

[2]

✓✓

Psoriasis

[18]

[12]

[2]

[1]

[5]

Purpura

[1]

[1]

[1]

[13]

[13]

[1]

Pustules

[1]

[1]

[1]

[1]

[1]

Rash

[6] (11%)

[1]

[4] (<10%)

[1] (<10%)

[1]

(<10%)

[1]

Stevens–Johnson syndrome

[1]

[4]

[1]

[2]

[25] (<10%)

[2]

[24] (<10%)

Thrombocytopenic purpura

[2]

[8]

Toxic epidermal necrolysis

[5]

[3]

[2]

[15]

[2]

[3]

[17]

Toxicity

[2]

[1]

Urticaria

[1]

[2]

[1]

[1]

[4]

[2]

[1]

[1]

[1]

[2]

Vasculitis

[1]

[3]

[5]

[5]

HAIR

Alopecia

[1]

[1]

[2] (80%)

[1]

?

Hair pigmentation

[10]

[7] (<10%)

NAILS

Discoloration

[1]

[1]

Nail pigmentation

[2]

[3]

[2]

MUCOSAL

Aphthous stomatitis

[1]

[1]

[1]

[1]

Gingival pigmentation

[1]

[1]

Glossitis

Oral edema

[1]

[1]

[1]

Oral mucosal eruption

[2]

[1]

Oral pigmentation

[12]

[7]

[4]

[1]

Oral ulceration

[3] (6%)

[1]

[1]

Stomatitis

[2]

[1]

Amo Amodiaquine; A/L Artemether/Lumefantrine; Art Artesunate; A/P Atovaquone/Proguanil; C Chloroquine; H Hydroxychloroquine; M Mefloquine; P Pyrimethamine; Quc Quinacrine; Qud Quinidine; Qun Quinine; S Sulfadoxine Benzodiazepines

A

Cln

Clo

D

L

M

O

=

SKIN

Acneform eruption

[1]

[1]

Anaphylaxis

[1]

[1]

Angioedema

[1]

[1]

[1]

[1]

Bullous dermatitis

[2]

[1]

Dermatitis

[5]

(<10%)

(<10%)

[3] (<10%)

(<10%)

(<10%)

Diaphoresis

(16%)

[1]

DRESS syndrome

[1]

[1]

Edema

(5%)

[2]

Erythema multiforme

[1]

[1]

[1]

Exanthems

[1]

[1]

[1]

[6]

Exfoliative dermatitis

[1]

[2]

Fixed eruption

[2]

[1]

[1]

Peripheral edema

[1]

Photosensitivity

[4]

[1]

Pruritus

[2] (<10%)

[1]

[3]

Pseudolymphoma

[1]

[2]

[2]

Purpura

[1]

[4]

Rash

[4] (11%)

[2]

✓✓

Urticaria

[1]

[1]

[1]

Vasculitis

[1]

[1]

MUCOSAL

Sialopenia

(33%)

Sialorrhea

(<10%)

(<10%)

[1]

(<10%)

Xerostomia

[6] (15%)

[1]

A Alprazolam; Cln Clonazepam; Clo Clorazepate; D Diazepam; L Lorazepam; M Midazolam; O Oxazepam Beta Blockers

A

B

C

N

P

S

=

SKIN

Anaphylaxis

[2]

[1]

Cold extremities

[1]

[6] (36%)

?

Dermatitis

[1]

[1]

[2]

Diaphoresis

[1]

Edema

[1]

(5%)

Fixed eruption

[1]

[1]

[1]

Leukocytoclastic vasculitis

[1]

[1]

Lichenoid eruption

[1]

[1]

[3]

[1]

Lupus erythematosus

[2]

[1]

[2]

Necrosis

[3]

[3]

Peripheral edema

(<10%)

Photosensitivity

[1]

Pruritus

(<5%)

[1]

(<10%)

Psoriasis

[7]

[1]

[20]

[3]

Rash

[1]

(<10%)

[2] (<10%)

Raynaud’s phenomenon

[2]

(<10%)

[3] (59%)

Urticaria

[2]

[3]

Vasculitis

[1]

[1]

HAIR

Alopecia

[1]

[6]

MUCOSAL

Xerostomia

[1]

A Atenolol; B Bisoprolol; C Celiprolol; N Nebivolol; P Propranolol; S Sotalol Biologics

Ald

Alm

Be

Bo

C

D

E

G

Ib

In

Ip

L

P

R

=

SKIN

Acne keloid

[1]

[1]

[2]

Acneform eruption

[5](10%)

[60] (92%)

[1] (<10%)

[26] (73–80%)

[32] (66–85%)

[2]

[1]

[17] (81%)

AGEP

[1]

[1]

[1]

[6]

Anaphylaxis

[5](13%)

[1]

[1]

[1]

[7]

Angioedema

[2]

[1]

[3]

[1]

[4](11%)

Bullae

[1]

Bullous dermatitis

[1]

[1]

[4]

[1]

Bullous pemphigoid

[1]

[1]

Cellulitis

[1]

(5%)

[1]

Dermatitis

[2]

[1]

[1]

[4] (80%)

(<10%)

[2] (14%)

[1](6%)

[11] (12%)

[1]

[2]

Dermatomyositis

[1]

[1]

Desquamation

[1]

[1] (8%)

[3] (89%)

[2] (39%)

[3] (13%)

?

Diaphoresis

(13%)

[1]

(8%)

[2](15%)

DRESS syndrome

[2]

[3]

[2]

Ecchymoses

[1] (16%)

[1](16%)

Eczema

[1]

(<10%)

[1]

[1]

[6](39%)

[2]

?

Edema

[3](47%)

[1](15%)

(23%)

[5](23%)

[1]

[33](80%)

[2](15%)

[1](10%)

[1](15%)

[1]

Embolia cutis medicamentosa (Nicolau syndrome)

[1]

[1]

Erythema

[5](41%)

[2]

[3](14%)

[1]

(18%)

[1]

[5](<10%)

[2]

[1]

(5%)

[5](65%)

[1](16%)

Erythema multiforme

[1]

[1](16%)

[1]

[1]

[1](16%)

Erythema nodosum

[3]

[1]

Erythroderma

[4]

[3]

Exanthems

[5]

[1]

[1](16%)

[5]

[3](8%)

[3](21%)

[8]

[3]

[5](20%)

[3](16%)

[1]

Exfoliative dermatitis

[1](18%)

[1]

[3]

[1]

[2](25%)

?

Facial edema

[1]

[2](<10%)

[1]

Fissures

[4](14%)

[1]

[4](21%)

?

Folliculitis

[2]

[12](83%)

[9](11%)

[4]

[2]

[3]

?

Graft-versushost reaction

[1]

[1]

[1](14%)

[2](43%)

?

Granulomas

[1]

[1]

[3]

Hand–foot syndrome

[11](57%)

[5](6%)

[3](30–60%)

[2]

[3]

[1](10%)

[1]

[3](23%)

Hematoma

[1]

[1]

Herpes simplex

[2](6%)

[2]

[2]

Herpes zoster

[3](9%)

[12](10–15%)

[6]

Hyperhidrosis

[1](8%)

(<10%)

[1]

[2](11%)

Hypersensitivity

[1](7%)

[8]

[1]

[1]

[5]

Kaposi’s sarcoma

[1]

[2]

[3]

Lesions

[1]

[1](8%)

Lichen planus

[5]

[8]

Linear IgA

[4]

[3]

Livedo reticularis

[1]

[2]

Lupus erythematosus

[1]

[1]

[1]

[1]

[17]

[1]

Malignancies

[1]

[6]

Necrolysis

[1]

[1]

Necrosis

[2]

[2]

[1]

[6]

[1]

Neutrophilic eccrine hidradenitis

[1]

[2]

Panniculitis

[3]

[2]

Papulopustular eruption

[6](83%)

[7](29%)

[3](21%)

[4](21–41%)

?

Pemphigus

[2]

[2]

[1]

Peripheral edema

(28%)

(13%)

[1](8%)

[5](83%)

[1](40%)

[3](44%)

[5](75%)

[3](83%)

[1](12%)

[1](14%)

Petechiae

(<10%)

Photosensitivity

[1]

[1]

[1](<10%)

[2]

Pigmentation

[1]

[1](16%)

[1]

[9](60%)

[3](21%)

[2](16%)

[1]

Pityriasis rubra pilaris

[1]

[1]

Pruritus

[7](24%)

(14–24%)

[1](91%)

[1](11%)

[9](40%)

[3](14%)

[8](21%)

[4](61%)

[3](10%)

[4](30%)

[17](47%)

[3](42%)

[9](91%)

[8](14%)

✓✓

Pseudo lymphoma

[1]

[3]

[1]

Psoriasis

[4]

[1]

[2]

[22]

[3]

?

Purpura

[1]

(8%)

[1]

[2]

[3]

[1]

[1]

[2]

[1]

[1]

Pustules

[1]

[1]

[1]

Radiation recall dermatitis

[1]

[1]

[1]

[1]

Rash

[2](42%)

[5](13–40%)

[15](91%)

[9](67%)

[46](89%)

[9](34%)

[105](80%)

[59](66–85%)

[23](69%)

[5](11%)

[24](61%)

[15] (36%)

[28](91%)

[12](58%)

✓✓

Rosacea

[1]

[2]

[1]

[1]

Sarcoidosis

[1]

[47]

[2]

[1]

?

Scleroderma

[2]

[1]

Seborrheic dermatitis

[1]

[1]

[2]

Serum sickness

[1](8%)

[22](<17%)

?

Skin reactions

[1]

[1]

Squamous cell carcinoma

[1]

[1]

[2]

[1](7%)

Stevens–Johnson syndrome

[1]

[1]

[11]

[1]

[5]

[5]

Sweet’s syndrome

[1]

[7]

[1]

[1]

[3]

Telangiectasia

[1]

[1]

[1]

[1]

[1]

Thrombocytopenic purpura

[9]

[1]

[2]

Toxic epidermal necrolysis

[2]

[2]

[1]

[1]

[1]

[1]

[3]

Toxicity

[6]

[9](16%)

[3](38%)

[18](63%)

[6](36%)

[7](84%)

[9](68%)

[8](30–44%)

[4]

[3](35%)

[6](75%)

[25](95%)

[2](12%)

Transient acantholytic dermatosis

[1]

[1]

Tumor lysis syndrome

[2](17%)

[1](<5%)

[1]

[3](<5%)

Tumors

[5](11%)

[1](11%)

Ulcerations

[3]

[1]

[1]

[2]

[1]

Urticaria

[3]

[2](16–30%)

(<10%)

[1]

[1]

[3]

[2]

[1]

[5](8%)

Vasculitis

[1]

[4]

[1]

[1]

[1]

[7]

[3]

Vitiligo

[3]

[9]

[3]

Xerosis

(15%)

[1]

[1](16%)

[14](49%)

(<10%)

[11](56%)

[11](53%)

[1](<10%)

[1]

[2](16%)

[12](62%)

HAIR

Abnormal hair growth

[2]

[1]

Alopecia

[2](10%)

[5](43%)

(5%)

[1](<10%)

[10](14%)

[6]

[1](10–15%)

[16](48%)

[1]

[3](54%)

[1]

Hair changes

[3]

[3]

[2](9%)

Hair pigmentation

[2]

[3](18%)

Hirsutism

[1]

[1]

Hypertrichosis

[3]

[4]

[2]

[3]

NAILS

Nail changes

[1](21%)

[2](17%)

[1](17%)

[2](9–29%)

?

Nail disorder

[2]

Nail pigmentation

[1]

[1]

Paronychia

[1]

[14](14%)

[11](15%)

[13](14–32%)

[12](85%)

?

Pyogenic granuloma

[1]

[1]

[2]

[1]

MUCOSAL

Aphthous stomatitis

[1](5%)

[1]

[1]

[1]

[2]

[1]

Epistaxis

[5](17%)

[1]

[1](17%)

(15%)

[1]

Mucocutaneous eruption

[1]

[1]

Mucosal inflammation

[1]

[1](18%)

[1]

(6%)

Mucositis

[9](75%)

[2](45%)

[10]

[1](16%)

[9](21%)

[4](6–17%)

[2](15%)

[4](75%)

Oral lichenoid eruption

[3]

[1]

Oral pigmentation

[3]

[1]

Oral ulceration

[1]

[2](18%)

[1]

[1]

[1]

[1]

[3](15%)

Oropharyngeal pain

[1]

[1]

Perianal fistula

[1](67%)

[1]

?

Rectal hemorrhage

[1]

[1]

Stomatitis

[1](22%)

[1](14%)

[8](75%)

[1](43%)

[3](25%)

[1]

[9](9–19%)

[7](6–17%)

[1](30%)

[4](100%)

[2](69%)

Xerostomia

[1]

(11%)

[1](33%)

[1](44%)

[4](41%)

(7%)

?

Ald Aldesleukin; Alm Alemtuzumab; Be Bevacizumab; Bo Bortezomib; C Cetuximab; D Dasatinib; E Erlotinib; G Gefitinib; I Imatinib; I Interferon Alfa; I Ipilimumab; L Lenalidomide; P Panitumumab; R Rituximab Bisphosphonates

A

E

I

P

R

Z

=

SKIN

Angioedema

[2]

Candidiasis

(6%)

(12%)

Eczema

[1](13%)

[1]

Edema

[3]

Exanthems

[1]

[1]

Hypersensitivity

[3](19%)

[1]

Peripheral edema

[1]

(8%)

(5–21%)

Pruritus

[1]

[1]

[1](4–5%)

Rash

[5]

[1]

[1]

[1] (8%)

[3](6%)

✓✓

Stevens–Johnson syndrome

[1]

[1]

Toxic epidermal necrolysis

[1]

[1]

Urticaria

[1]

[1]

HAIR

Alopecia

[1]

[1](12%)

MUCOSAL

Stomatitis

[1]

(8%)

A Alendronate; E Etidronate; I Ibandronate; P Pamidronate; R Risedronate; Z Zoledronate Calcium Channel Blockers

A

D

F

I

Nic

Nif

Nis

V

=

SKIN

Acneform eruption

[1]

[1]

AGEP

[21]

[3]

?

Anaphylaxis

[1]

[1]

Angioedema

[6](6%)

[3]

[1]

[1]

[2]

[3]

Dermatitis

(<10%)

[1]

[1]

Diaphoresis

[2]

[1]

[2]

[2]

Ecchymoses

[1]

Eczema

[1]

[1]

Edema

[20](5–14%)

[4](<10%)

[1]

[6](7%)

[3]

[1]

[1]

✓✓

Erythema

[2]

[2]

Erythema multiforme

[2]

[11](31%)

[5]

[4]

Erythema nodosum

[2]

[1]

Exanthems

[2]

[17](31%)

[2]

[2]

[9]

[1]

[8]

Exfoliative dermatitis

[6]

[5]

[2]

Facial edema

Hyperkeratosis

[1]

[2]

Hypersensitivity

[1]

[2]

Lichenoid eruption

[1]

[3]

Linear IgA

[1]

[1]

Lupus erythematosus

[5]

[3]

[2]

Peripheral edema

[44](34%)

[1](5–8%)

[6](22%)

[2](7%)

[12](6%)

[6](22%)

[1](<10%)

Petechiae

[1]

Photosensitivity

[11]

[5]

[4]

Pigmentation

[2]

[10]

Pruritus

[3]

[6]

[1](6%)

[3]

[6]

Pseudolymphoma

[1]

[1]

Purpura

[1]

[3]

[1]

[3]

[1]

Pustules

[2]

Rash

(<10%)

[4]

[3]

[2]

[2]

✓✓

Stevens–Johnson syndrome

[1]

[4]

[3]

[5]

Telangiectasia

[5]

[2]

[2]

Toxic epidermal necrolysis

[2]

[4]

[2]

Toxicity

[2]

[2]

[1]

Ulcerations

[1]

Urticaria

[1]

[5]

[1]

[3]

[7]

[5]

✓✓

Vasculitis

[2]

[6]

[4]

[2]

Xerosis

HAIR

Alopecia

[2]

[4]

[5]

Hair pigmentation

[1]

[1]

NAILS

Nail dystrophy

[1]

[1]

[1]

MUCOSAL

Gingival hyperplasia/hypertrophy

[28](31%)

[10](21%)

[5](2–10%)

[1]

[2]

[74](75%)

[10](19%)

✓✓

Oral ulceration

[1]

[1]

Xerostomia

[1]

[2]

[1]

✓✓

A Amlodipine; D Diltiazem; F Felodipine; I Isradipine; Nic Nicardipine; Nif Nifedipine; Nis Nisoldipine; V Verapamil Cephalosporins

Cdxl

Cclor

Ctan

Coxm

Cnir

Cixm

Ctxm

Czim

Caxn

Cpm

CF

Cple

=

SKIN

AGEP

[2]

[2]

[1]

[1]

[4]

[1]

Anaphylaxis

[4]

[3]

[7]

[1]

[1]

[3]

[14]

Angioedema

[1]

[3]

Candidiasis

[3](5%)

Dermatitis

[1]

[2]

DRESS syndrome

[1]

[1]

[4]

[2]

Erythema

[1]

[1]

(9%)

Erythema multiforme

[6]

[1](13%)

[2]

[1]

[1]

Exanthems

[1]

[9]

[2](6%)

[3]

[1]

[7](6%)

Fixed eruption

[2]

[1]

[1]

Hypersensitivity

[1]

[4]

[1]

[2]

[1]

[4]

[2]

[2]

[1]

Jarisch–Herxheimer reaction

[1]

[1]

Lupus erythematosus

[1]

[2]

Pemphigus

[1]

[1]

[1]

[1]

Pemphigus erythematodes

[1]

[2]

Pruritus

[1]

[4]

[1]

[3]

[3]

[2]

[3]

[7]

[1](9%)

✓✓

Pseudolymphoma

[1]

[1]

Pustules

[1]

[1]

Rash

[1]

[2]

[1]

[2]

[3]

[4]

[5]

[12](51%)

[7](10%)

[1]

✓✓

SDRIFE

[1]

[1]

Serum sickness

[31]

[2]

[1]

[2]

Stevens–Johnson syndrome

[1]

[1]

[1]

[1]

[1]

Toxic epidermal necrolysis

[1]

[2]

[1]

[1]

[1]

Urticaria

[2]

[5]

[2]

[2](13%)

[4]

[1]

MUCOSAL

Glossitis

[1]

[2]

Oral candidiasis

[1]

[1]

Oral mucosal eruption

[1]

[1]

Ist generation: Cdxl Cefadroxil; 2nd generation: Cclor Cefaclor, Ctan Cefotetan, Coxm Cefuroxime; 3rd generation: Cnir Cefdinir, Cixm Cefixime, Ctxm Cefotaxime, Czim Ceftazidime, Caxn Ceftriaxone; 4th generation: Cpm Cefepime; 5th generation: CF Ceftaroline Fosamil; Cple Ceftobiprole Disease-Modifying Antirheumatic Drugs (DMARDS)

Ab

Ad

Az

Ce

Cy

E

G

H

I

M

P

R

S

=

SKIN

Abscess

[1]

[2]

[4]

[2]

Acneform eruption

[2]

[2]

[7](13%)

[1]

[6]

[1](67%)

?

AGEP

[2]

[1]

[22](25%)

[2]

[3]

?

Anaphylaxis

[1]

[1]

[8]

[2]

[1]

[10]

[9](<10%)

[7]

[4]

Angioedema

[3]

[2]

[1]

[1]

[1]

[1]

[4](11%)

[2]

Angioma

[1]

[1]

Atrophy

[1]

[1]

Basal cell carcinoma

[3]

[1]

[4]

[1]

[1]

[1]

Bullous dermatitis

[1]

[2]

[1]

[4]

[3]

[1]

Bullous pemphigoid

[1]

[1]

[6]

[3]

Burning

[1]

[1]

Candidiasis

[1]

[2](16%)

[4](5%)

[1]

[1]

Carcinoma

[2]

[3]

[2]

[2]

Cellulitis

[1]

[2](<5%)

[2]

[5]

[1]

[1]

Churg-Strauss syndrome

[1]

[1]

Cicatricial pemphigoid

[1]

[2]

Cyst

[5]

[1]

Dermatitis

[1]

[4]

[3]

[1]

[4]

[2]

[4]

[2]

[2]

Dermatomyositis

[5]

[4]

[1]

[14]

Diaphoresis

[2](15%)

[1]

DRESS syndrome

[2]

[31](7%)

?

Ecchymoses

[1]

[1]

[1]

Eccrine squamous syringometaplasia

[1]

[1]

Eczema

[2](15%)

[2]

[5](19–30%)

[1]

?

Edema

[1](5–14%)

[3]

[2]

[1]

[1]

Erysipelas

[1]

(<5%)

Erythema

[1]

[1]

[1]

[1]

[1](16%)

Erythema annulare centrifugum

[3]

[1]

Erythema multiforme

[1]

[2]

[1]

[2]

[4]

(<5%)

[8]

Erythema nodosum

[1]

[4]

[1]

[1]

[1]

[1]

[2]

Erythroderma

[2]

[2]

[1]

Exanthems

[10](5%)

[1]

[2]

[4](<5%)

[4]

[5](15%)

[8]

[1]

[23](23%)

Exfoliative dermatitis

[1]

[3]

[5]

Facial edema

[1]

[1]

[1]

[1]

[1]

[1]

[1]

Fixed eruption

[1]

[1]

[1]

[1]

[7]

Folliculitis

[8]

[1]

[2]

[2]

Fungal dermatitis

[1](42%)

[1]

?

Furunculosis

[1]

[1]

[1]

Granuloma annulare

[1]

[1]

Granulomas

[1]

[2]

[1]

Granulomatous reaction

[5]

[5]

[1]

[1]

Henoch–Schönlein purpura

[2]

[3]

[1]

Herpes

[1]

[1]

Herpes simplex

[3](<5%)

[1]

[3](35%)

[4]

[1]

[4](10%)

[2]

[2]

Herpes zoster

[3]

[9]

[8](27%)

[2]

[2]

[5]

[10]

[7]

[6]

Hidradenitis

[2]

[1]

[2]

[1]

[1]

Hyperkeratosis

[1]

[1]

Hypersensitivity

[2]

[3]

[27]

[2]

[1]

[11](11%)

[2]

[3]

[5]

[16](<5%)

Kaposi’s sarcoma

[1]

[14]

[5]

[1]

[3]

Keratoacanthoma

[1]

[1]

[1]

Leprosy

[1]

[2]

[1]

Leukocytoclastic vasculitis

[1]

[1]

[1]

Lichen planus

[2]

[1]

[2]

[4]

[3]

Lichenoid eruption

[5]

[1]

[1]

[3]

[4]

[3]

[7]

Linear IgA

[2]

[1]

Lupus erythematosus

[16]

[1]

[25]

[3]

[33]

[43]

[1]

[34]

Lupus syndrome

[3]

[2]

[2]

[11]

[1]

Lymphadenopathy

[1]

[1]

[1]

Lymphoma

[8]

[1]

[12]

[3]

[9]

[5]

[1]

Lymphomatoid papulosis

[1]

[1]

Lymphoproliferative disease

[4]

[2]

[1]

[1]

[1]

[1]

Malignancies

[10](23%)

[3]

[1]

[2](8%)

[3]

[5]

[2]

[1]

Melanoma

[6]

[1]

[2]

[1]

[1]

[1]

Molluscum contagiosum

[1]

[2]

[2]

Morphea

[1]

[1]

[2]

Necrosis

[4]

[1]

[1]

Necrotizing fasciitis

[1]

[1]

[1]

[1]

Neoplasms

[1]

[2]

[2]

[1]

[2]

[2]

[2]

[1]

Neutrophilic dermatosis

[1]

[1]

[4](76%)

?

Nevi

[3]

[1]

[2]

Nodular eruption

[1]

[3]

[15]

Non-Hodgkin’s lymphoma

[1]

[1]

[2]

Palmar–plantar pustulosis

[3]

[1]

Pemphigus

[1]

[75]

[1]

?

Pemphigus foliaceus

[1]

[16]

Peripheral edema

[1]

(<5%)

[1]

[3](10%)

[1]

[1]

(<10%)

[1](14%)

Photoallergic reaction

[1]

[1]

Photosensitivity

[1]

[6]

[9](5%)

[4](10%)

Phototoxicity

[3]

[1]

Pigmentation

[1](37%)

[17](<10%)

(<10%)

[3]

?

Pityriasis lichenoides chronica

[1]

[1]

[2]

Porokeratosis

[4]

[1]

[1]

Pruritus

[5]

[1]

[1]

[2](12%)

[2](14%)

[12](47%)

[8](20%)

[1](<5%)

[2](44–50%)

[8](14%)

[7](10%)

Pseudolymphoma

[1]

[6]

[1]

[2]

[10]

[2]

Psoriasis

[12]

[38]

[6]

[2]

[19]

[2]

[12]

[51](19%)

[4]

[3]

[1]

Purpura

[4]

[5]

[1]

[1]

Pustules

[1]

[2]

[1]

[5]

[2]

Pyoderma gangrenosum

[1]

[1]

Rash

[6](23%)

[4](12%)

[10](<10%)

[2](5%)

[1](7–12%)

[7](15%)

[3]

[4](<10%)

[13](25%)

[11](5%)

[6](44–50%)

[12](58%)

[19](6%)

✓✓

Raynaud’s phenomenon

[2]

[1]

[3]

Rosacea

[1]

[1]

[1]

Sarcoidosis

[6]

[8]

[3]

[1]

[1]

[1]

Scabies

[5]

[1]

[1]

Scleroderma

[1]

[1]

[7]

Serum sickness

[6]

[1]

[22](<17%)

[3]

?

Sjogren’s syndrome

[4]

[1]

Skin cancer

[1]

[1]

Squamous cell carcinoma

[5]

[5]

[10]

[12]

[4]

[1]

[1]

[2]

Stevens–Johnson syndrome

[2]

[1]

[1]

[1]

[4]

[5]

[9]

Striae

[1]

[1](9%)

Sweet’s syndrome

[12]

[1]

[1]

Thrombocytopenic purpura

[1]

[5]

[2]

Tinea

[1]

[3]

Toxic epidermal necrolysis

[1]

[1]

[3]

[2]

[8]

[2]

[3]

[13](<10%)

Toxicity

[1]

[3](6%)

[1]

[2]

[1]

[1]

[2](75%)

[6](10%)

[2](12%)

Tumors

[1]

[8](5%)

[1]

[1]

[1](11%)

Ulcerations

[1]

[1]

[11]

Urticaria

[1]

[3]

[5]

[2]

[2]

[2]

[6](17%)

[4]

[2](44–50%)

[5](8%)

[10](<5%)

Vasculitis

[2]

[8](13%)

[5]

[3]

[21](25%)

[1]

[16](63%)

[9]

[7]

[3]

[4]

✓✓

Vesiculation

[1]

[1]

[1]

Vitiligo

[2]

[1]

[4]

Xerosis

[1]

[1]

[1]

HAIR

Alopecia

[3]

[9](54%)

[1]

[2]

[4](20%)

[1]

[4]

[25](10%)

[3]

[1]

[6]

Alopecia areata

[7]

[6]

[1]

[1]

[3]

Follicular mucinosis

[1]

[1]

Hair pigmentation

[7](<10%)

[1]

Hirsutism

[10]

[2]

NAILS

Discoloration

[1]

[1]

Leukonychia (Mees’ lines)

[2]

[1]

[1]

Nail pigmentation

[3]

[2]

[4]

Onychocryptosis

[1]

[1]

[1]

Onycholysis

[1]

[1]

Onychomycosis

[2](5%)

[1](33%)

[1]

?

Pyogenic granuloma

[1]

[1]

MUCOSAL

Aphthous stomatitis

[2](9%)

[2]

[2]

[1]

Cheilitis

[1](10%)

[1]

[1]

Gingival hyperplasia/hypertrophy

[156](86%)

[1]

?

Gingivitis

[1](7%)

[1]

Glossitis

[1]

[1]

Mucocutaneous reactions

[1]

[2]

[1]

[2]

[2](6%)

Mucosal ulceration

[1]

[1]

Oral candidiasis

[1]

[1](11%)

[1]

Oral mucositis

[1]

[1]

[6]

Oral ulceration

[2]

[2]

[1]

[10](61%)

[5]

[3]

?

Oropharyngeal pain

[1](9%)

[1]

Stomatitis

[3](24%)

[1]

(5–7%)

[2]

[17](43%)

[6]

[2](69%)

[1](<10%)

Ab Abatacept; Ad Adalimumab; Az Azathioprine; Ce Certolizumab; Cy Cyclosporine; E Etanercept; G Golimumab; H Hydroxychloroquine; I Infliximab; M Methotrexate; P Penicillamine; R Rituximab; S Sulfasalazine DPP-4 Inhibitors

Alog

Lina

Saxa

Sita

=

SKIN

Anaphylaxis

[1]

[1]

Angioedema

[1]

[1]

[3]

Edema

[1]

[3]

Exfoliative dermatitis

Hypersensitivity

[2]

[1]

[1]

Peripheral edema

[1]

[1](10%)

Pruritus

[2]

[1]

[1]

Rash

[1]

[1]

[1]

Stevens–Johnson syndrome

[1]

[1]

Urticaria

[1]

Alog Alogliptin; Lina Linagliptin; Saxa Saxagliptin; Sita Sitagliptin Egfr Inhibitors

C

E

G

L

Nec

Nil

P

Sor

Sun

=

SKIN

Acneform eruption

[60](92%)

[26](73–80%)

[32](66–85%)

[8](90%)

[1](23–43%)

[1](<10%)

[17](81%)

[5](<10%)

[1](<10%)

✓✓

AGEP

[1]

[1]

[2]

Anaphylaxis

[5](13%)

[1]

[1]

Angioedema

[1]

[1]

Bullous dermatitis

[1]

[1](7%)

Dermatitis

[4](80%)

[2](14%)

(<10%)

?

Desquamation

[3](89%)

[2](39%)

[3](13%)

[9](50%)

?

DRESS syndrome

[2]

[1]

Eczema

[1]

[1]

[1]

(<10%)

[2]

[1]

Edema

[1]

[2](29%)

[2]

[1](15%)

[3](11%)

[6](32%)

Erythema

[3](14%)

(18%)

[1]

[2]

[2](<10%)

[5](65%)

[4](19%)

[5](7%)

Erythema multiforme

[1]

[10](17%)

Exanthems

[5]

[3](8%)

[3](21%)

[2]

[1]

[3]

Exfoliative dermatitis

[1]

[2](14%)

[1]

[2](25%)

[1](<10%)

[1](10%)

Facial edema

[1]

[1]

[2]

Fissures

[4](14%)

[1]

[1](22%)

[4](21%)

?

Folliculitis

[12](83%)

[9](11%)

[4]

[2]

(<10%)

[3]

[3]

Hand–foot syndrome

[5](6%)

[3](30–60%)

[2]

[16](76%)

[3](23%)

[97](89%)

[61](45–65%)

Hematoma

[1]

(<10%)

Hypersensitivity

[8]

[1]

[2]

Jaundice

[2](35%)

[1]

?

Keratosis pilaris

[1]

[1]

[1]

Necrosis

[1]

[1]

Nevi

[1]

[2]

[2]

Papulopustular eruption

[6](83%)

[7](29%)

[3](21%)

[4](21–41%)

?

Peripheral edema

[1](40%)

[1](44%)

[1](12%)

[1](17%)

Pigmentation

[1]

[2](18%)

[1]

[2]

[12](38%)

Pruritus

[9](40%)

[8](21%)

[4](61%)

[6](33%)

[2](60%)

[8](9–21%)

[9](91%)

[10](21%)

[3](<10%)

✓✓

Psoriasis

[1]

[2]

[1]

[2]

Purpura

[3]

[1]

Pustules

[1]

[1]

[1]

Pyoderma gangrenosum

[1]

[4]

Radiation recall dermatitis

[1]

[1]

[3]

[1]

Rash

[46](89%)

[105](80%)

[59](66–85%)

[48](55%)

[7](53%)

[10](56%)

[28](91%)

[46](30–75%)

[47](14–38%)

✓✓

Rosacea

[1]

[2]

[1]

Seborrheic dermatitis

[1]

[1]

[1]

Skin reactions

[1]

[1]

Squamous cell carcinoma

[1]

[1]

[7]

Stevens–Johnson syndrome

[1]

[1]

Telangiectasia

[1]

[1]

[1]

Toxic epidermal necrolysis

[2]

[1]

Toxicity

[18](63%)

[7](84%)

[9](68%)

[12](46%)

[1](8%)

[6]

[25](95%)

[14](75%)

[20](67%)

✓✓

Ulcerations

[1]

[2]

[1]

Urticaria

[1]

(<10%)

Vasculitis

[1]

[1]

[1]

Xerosis

[14](49%)

[11](56%)

[11](53%)

[2](29%)

[2](67%)

[12](62%)

[6](14%)

[3](17%)

HAIR

Alopecia

(5%)

[10](14%)

[6]

[4](33%)

[2](<10%)

[3](54%)

[24](67%)

[3](5–12%)

Hair changes

[3]

[3]

[2](9%)

Hair pigmentation

[1]

[7](38%)

?

Hypertrichosis

[3]

[4]

[2]

NAILS

Nail changes

[1](21%)

[2](17%)

[1](17%)

[2](9–29%)

?

Nail disorder

[2]

[2](10%)

[1](<10%)

Paronychia

[14](14%)

[11](15%)

[13](14–32%)

[6](27%)

[12](85%)

Pyogenic granuloma

[1]

[1]

[2]

[1]

Splinter hemorrhage

[3](70%)

[1]

?

Subungual hemorrhage

[1]

[3]

MUCOSAL

Aphthous stomatitis

[1]

[1]

[1]

Cheilitis

[2](14%)

[1]

Epistaxis

[1]

[1]

[2](11%)

[2](13%)

Glossodynia

(<10%)

[1](15%)

Mucosal inflammation

[1](18%)

[2](15%)

(6%)

[4](54%)

?

Mucositis

[10]

[9](21%)

[4](6–17%)

[4](11–35%)

[4](75%)

[12](28%)

[16](~60%)

Oral mucositis

[1](33%)

(6%)

[1](20%)

?

Oral ulceration

[1]

[1]

[1]

[1](5%)

Oropharyngeal pain

[1](10%)

Stomatitis

[3](25%)

[9](9–19%)

[7](6–17%)

[2](41%)

(11%)

[4](100%)

[11](28%)

[15](60%)

Xerostomia

(11%)

[1](11%)

[1](<10%)

[2](~60%)

?

C Cetuximab; E Erlotinib; G Gefitinib; L Lapatinib; Nec Necitumumab; Nil Nilotinib; P Panitumumab; Sor Sorafenib; Sun Sunitinib Fluoroquinolones

B

C

L

M

N

=

SKIN

AGEP

[3]

[1]

[1]

Anaphylaxis

[15]

[5]

[5]

Bullous dermatitis

[1]

[2]

[1]

Candidiasis

[2]

Diaphoresis

[4]

Edema

Erythema

[2]

Erythema multiforme

[5]

[1]

Erythema nodosum

[1]

Exanthems

[4]

[2]

[2]

Fixed eruption

[12]

[2]

Hypersensitivity

[1]

[5]

[5]

[6]

Photosensitivity

[18]

[3]

[5]

[1]

Phototoxicity

[5]

[5]

[4]

Pigmentation

[1]

Pruritus

[10]

[2]

[2]

[1]

Purpura

[4]

[2]

Radiation recall dermatitis

[1]

[2]

Rash

[12](<10%)

[1]

[3]

Stevens–Johnson syndrome

[8]

[2]

[1]

Sweet’s syndrome

[1]

[1]

Thrombocytopenic purpura

[1]

[2]

Toxic epidermal necrolysis

[10]

[5]

[2]

[2]

Toxicity

[2]

[1]

Urticaria

[8]

[3]

[1]

Vasculitis

[11]

[3]

MUCOSAL

Stomatitis

[3]

[1]

Xerostomia

[3]

[1]

B Besifloxacin; C Ciprofloxacin; L Levofloxacin; M Moxifloxacin; N Norfloxacin Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

A

C

D

E

F

Ib

In

Ktp

Ktl

Mx

Np

O

P

Su

=

SKIN

AGEP

[2]

[7]

[1]

[5](50%)

[1]

[1]

?

Anaphylaxis

[16](<10%)

[8]

[16](48%)

[1]

[5](25%)

[4]

[3]

[1]

[2]

[4]

Angioedema

[64](22%)

[9]

[2]

[1]

[1]

[8]

[2]

[1]

[1]

[3]

[5]

[3]

✓✓

Bullous dermatitis

[8]

[1]

[2]

[3]

[2]

[1](29%)

[5]

[1]

Bullous pemphigoid

[2]

[1]

[1]

[2]

Churg-Strauss syndrome

[2]

[1]

Dermatitis

[2]

[9]

[1]

[5]

[5]

[29]

(3–9%)

[5]

[1]

Dermatitis herpetiformis

[2]

[2]

[1]

[1]

[2]

Dermatomyositis

[2]

[1]

Diaphoresis

[1]

[1]

[2](<10%)

[3]

[1]

DRESS syndrome

[2]

[1]

[1]

[4]

[4]

[1]

Ecchymoses

[1]

[1]

(3–9%)

Eczema

(3–9%)

[1]

[1]

[3]

[1]

Edema

[5](6%)

(3–9%)

[1]

[1](3–9%)

(<10%)

[1](6%)

[1](<9%)

Embolia cutis medicamentosa (Nicolau syndrome)

[16]

[2]

[1]

[1]

Erythema

[2](14%)

[4]

[3](21%)

[1]

[2]

[1]

[1]

[1]

Erythema multiforme

[18]

[3]

[6]

[11](13%)

[1]

[1]

[1]

[2]

[1]

[12]

[8]

Erythema nodosum

[18]

[1](<5%)

[1]

[1]

Erythroderma

[4]

[2]

Exanthems

[22](18%)

[7](49%)

[6](<5%)

[2]

[3]

[9]

[7](11%)

[3]

[1](3–9%)

[1]

[9](14%)

[1]

[8]

[9](<5%)

✓✓

Excoriations

[1](6%)

[1]

Exfoliative dermatitis

[2]

[1]

[1]

[1]

[1]

[1]

Facial edema

[1]

[1]

[2]

[1]

Fixed eruption

[42]

[2]

[4](18%)

[2]

[2]

[14]

[2]

[1]

[24](24%)

[15]

[5]

Hematoma

[2]

[2]

[3]

Herpes simplex

[2]

[1]

Herpes zoster

[1]

Hot flashes

[1]

Hypersensitivity

[10]

[8]

[4]

[4]

[5]

[2]

[2](5%)

[2]

Jaundice

[1]

[1]

[1]

Lichen planus

[1]

[3]

[1]

Lichenoid eruption

[4]

[3]

[5]

Linear IgA

[6]

[1]

[1]

[1]

[3]

Lupus erythematosus

[1]

[5]

[2]

[1]

Pemphigus

[2]

[1]

[1]

[1]

[3]

Peripheral edema

[2]

[2]

[1]

[1]

[2](5%)

[1]

[1]

[1]

Petechiae

Photoallergic reaction

[1]

[1]

[2]

Photosensitivity

[4]

[1]

[6]

[1]

[34](11%)

[16]

[40]

[2]

Phototoxicity

[1]

[1]

Pityriasis rosea

[6]

[1]

Pruritus

[12]

[6]

[6](<10%)

[7](<10%)

[1](<5%)

[5](<5%)

[3](<10%)

[4](<10%)

[1](<10%)

[3]

[5](17%)

(<10%)

[6](<10%)

[5](<10%)

✓✓

Pseudolymphoma

[2]

[1]

[1]

[1]

[1]

[1]

[1]

[1]

Psoriasis

[6]

[1]

[2]

[7]

[1]

[1]

Purpura

[16]

[1]

[2]

[1]

[5]

[1]

[1](<10%)

[4]

[2]

[2]

Purpura fulminans

[2]

[1]

Pustules

[1]

[2]

Rash

(<10%)

[11](40%)

[4](6%)

[5]

[2]

[1]

[1]

[1](<10%)

[3]

[2](3–9%)

[2]

[1]

✓✓

SDRIFE

[2]

[1]

[1]

Serum sickness

[1]

[1]

[1]

Stevens–Johnson syndrome

[12]

[2]

[5]

[10](17%)

[1]

[1]

[2]

[2]

[5]

✓✓

Toxic epidermal necrolysis

[18]

[5]

[4]

[1]

[8](6%)

[6]

[1]

[1]

[5]

[4]

[12]

[13]

✓✓

Urticaria

[144](83%)

[11]

[7]

[10]

[7]

[6]

[1]

[4]

[6](<5%)

[7]

[4]

✓✓

Vasculitis

[4]

[4]

[3]

[2]

[1]

[8]

[5]

[1]

[9]

[3]

Vesiculobullous eruption

[2]

[1]

Wound complications

[1]

[1]

Xerosis

[3]

[1]

[1]

HAIR

Alopecia

[2]

[3]

[2]

[1]

[3]

[3]

NAILS

Nail changes

[1]

Onycholysis

[1]

[1]

MUCOSAL

Aphthous stomatitis

[6]

[1]

[1]

[1]

[4]

Epistaxis

[2]

[1]

Glossitis

Oral lesions

[1]

[2](7%)

[1]

Oral lichenoid eruption

[2]

[1]

[1]

[1]

Oral mucosal eruption

[6]

[2]

Oral mucosal fixed eruption

[1]

[1]

Oral ulceration

[8]

[1]

[1]

[4]

[1]

[1]

Rectal hemorrhage

[1]

Rectal mucosal ulceration

[2]

[1]

Stomatitis

[4](8%)

(<10%)

[2]

Tongue edema

[1]

[1]

Ulcerative stomatitis

[1]

Xerostomia

[2](26%)

[1]

[2]

[2]

[2]

A Aspirin; C Celecoxib; D Diclofenac; E Etodolac; F Flurbiprofen; Ib Ibuprofen; In Indomethacin; Ktp Ketoprofen; Ktl Ketorolac; Mx Meloxicam; Np Naproxen; O Oxaprozin; P Piroxicam; Su Sulindac Proton Pump Inhibitors (PPI)

D

E

L

O

P

R

=

SKIN

Acneform eruption

AGEP

[1]

[2]

Anaphylaxis

[1]

[6]

[7]

[7]

Angioedema

[5]

Candidiasis

Dermatitis

[1]

[1]

Diaphoresis

[1]

[1]

[1]

Ecchymoses

Eczema

[1]

Edema

[1]

[2](<10%)

Erythema multiforme

[2]

[1]

Erythroderma

[1]

[2]

Exanthems

[1]

Exfoliative dermatitis

[1]

[1]

[3]

Facial edema

[2]

[1]

[1]

Fixed eruption

[2]

[1]

Fungal dermatitis

Herpes zoster

Hypersensitivity

[3]

[2]

[1]

[1]

Lichenoid eruption

[1]

[2]

[1]

Lupus erythematosus

[2]

[3]

[5]

[3]

Peripheral edema

[2]

[2]

[2]

Photosensitivity

[1]

[1]

Pigmentation

[1]

Pruritus

[1](3–10%)

[8](<10%)

[1]

[2]

✓✓

Pruritus ani et vulvae

[1]

Psoriasis

[1]

Rash

[1]

(3–10%)

[6]

[2]

[2]

✓✓

Stevens–Johnson syndrome

[1]

Sweet’s syndrome

[1]

[1]

Toxic epidermal necrolysis

[4]

[5]

Urticaria

[3]

[8](<10%)

[2]

✓✓

Vasculitis

[2]

[1]

Xerosis

[1]

[2]

HAIR

Alopecia

[2]

MUCOSAL

Gingivitis

Glossitis

[1]

Oral candidiasis

[3]

Stomatitis

[2]

[1]

Tongue edema

[1]

Xerostomia

[2](<10%)

✓✓

D Dexlansoprazole; E Esomeprazole; L Lansoprazole; O Omeprazole; P Pantoprazole; R Rabeprazole Statins

A

F

L

Pi

Pr

R

S

=

SKIN

Acneform eruption

[1](36%)

?

Dermatomyositis

[3]

[1]

[1]

[2]

[5]

Diaphoresis

[1]

Ecchymoses

Eczema

[1]

[4](5%)

Edema

[1](6%)

[1]

Eosinophilic fasciitis

[1]

[2]

Erythema multiforme

[1]

[2]

Exanthems

[3](5%)

[1]

Herpes zoster

[1]

[1]

[1]

[1]

[1]

[1]

Hypersensitivity

[1]

[1]

Jaundice

[2]

[1]

Lichenoid eruption

[1]

[1]

[1]

[2]

[1]

Lupus erythematosus

[2]

[2]

[4]

[1]

[5]

Peripheral edema

[2](50%)

?

Petechiae

[1]

Photosensitivity

[1]

[7]

Pruritus

[1]

[2](5%)

[2]

[3]

Purpura

[1]

[1]

[3]

Radiation recall dermatitis

[1]

[1]

Rash

[2]

[3](5%)

[7](5–7%)

[3](<10%)

✓✓

Toxicity

[2]

[1]

[1]

Urticaria

[1]

[1]

Vasculitis

[1]

[2]

HAIR

Alopecia

[1]

MUCOSAL

Cheilitis

[1]

Stomatitis

[1](64%)

?

A Atorvastatin; F Fluvastatin; L Lovastatin; Pi Pitavastatin; Pr Pravastatin; R Rosuvastatin; S Simvastatin Tnf Inhibitors

A

C

E

G

I

=

SKIN

Abscess

[1]

[2]

[4]

Acneform eruption

[2]

[1]

[6]

AGEP

[1]

[2]

Anaphylaxis

[1]

[2]

[10]

Angioedema

[3]

[1]

[1]

Basal cell carcinoma

[1]

[1]

Bullous pemphigoid

[1]

[1]

Candidiasis

[1]

[4](5%)

Carcinoma

[2]

[2]

Cellulitis

[2](<5%)

[2]

[5]

Dermatitis

[1]

[3]

[4]

Dermatomyositis

[5]

[4]

Eczema

[2]

[5](19–30%)

?

Erythema

[1]

[1]

Erythema multiforme

[1]

[2]

Erythema nodosum

[1]

[1]

Exanthems

[2]

[4]

Fixed eruption

[1]

[1]

[1]

Folliculitis

[1]

[2]

Granuloma annulare

[1]

[1]

Granulomas

[1]

[2]

[1]

Granulomatous reaction

[5]

[5]

[1]

Henoch–Schönlein purpura

[2]

[3]

[1]

Herpes simplex

[1]

[1]

[4](10%)

Herpes zoster

[9]

[2]

[5]

[10]

Hidradenitis

[2]

[2]

[1]

Hypersensitivity

[3]

[1]

[11](11%)

Kaposi’s sarcoma

[1]

[1]

Leprosy

[1]

[2]

[1]

Leukocytoclastic vasculitis

[1]

[1]

[1]

Lichen planus

[2]

[2]

Lichenoid eruption

[5]

[3]

[3]

Lupus erythematosus

[16]

[25]

[3]

[33]

Lupus syndrome

[3]

[2]

[2]

[11]

Lymphadenopathy

[1]

[1]

Lymphoma

[8]

[3]

[9]

Lymphoproliferative disease

[1]

[1]

Malignancies

[3]

[3]

[5]

[2]

Melanoma

[6]

[2]

[1]

[1]

Molluscum contagiosum

[1]

[2]

Morphea

[1]

[1]

Necrotizing fasciitis

[1]

[1]

Neoplasms

[1]

[2]

[2]

[2]

Nevi

[1]

[2]

Peripheral edema

(<5%)

[1]

[1]

Pityriasis lichenoides chronica

[1]

[1]

[2]

Pruritus

[5]

[1]

[2](14%)

[8](20%)

Pseudolymphoma

[1]

[1]

[2]

Psoriasis

[38]

[6]

[19]

[2]

[51](19%)

✓✓

Pustules

[1]

[2]

[5]

Rash

[4](12%)

[2](5%)

[7](15%)

[3]

[13](25%)

✓✓

Rosacea

[1]

[1]

[1]

Sarcoidosis

[6]

[8]

[3]

Serum sickness

[6]

Skin cancer

[1]

[1]

Squamous cell carcinoma

[5]

[4]

[1]

[1]

Stevens–Johnson syndrome

[2]

[1]

Toxicity

[1]

[1]

[1]

[2](75%)

Tumors

[1]

[1]

Urticaria

[3]

[2]

[6](17%)

Vasculitis

[8](13%)

[21](25%)

[16](63%)

✓✓

Vitiligo

[2]

[4]

HAIR

Alopecia

[3]

[1]

[4](20%)

[4]

Alopecia areata

[7]

[1]

[1]

[3]

Follicular mucinosis

[1]

[1]

A Adalimumab; C Certolizumab; E Etanercept; G Golimumab; I Infliximab Tyrosine-Kinase Inhibitors

Aft

Axt

Cbo

Crz

Dsa

Erl

Gft

Imt

Lpt

Lnv

Nlo

Nnt

Srf

Snt

Vnd

=

SKIN

Acneform eruption

[24](92%)

[1](<10%)

[26](73–80%)

[32](66–85%)

[2]

[4](90%)

[1](<10%)

[5](<10%)

[1](<10%)

[3](35%)

AGEP

[1]

[1]

[6]

[2]

Bullous dermatitis

[1]

[1](7%)

Dermatitis

[1](21%)

(<10%)

[2](14%)

(<10%)

[1]

?

Desquamation

[2](39%)

[9](50%)

?

Diaphoresis

(13%)

[1](6%)

DRESS syndrome

[2]

[3]

[1]

Eczema

(<10%)

[1]

[1]

(<10%)

[1]

Edema

[9](38%)

[5](23%)

[1]

[33](80%)

[1](29%)

[2]

[3](11%)

[6](32%)

Erythema

[1]

(11%)

[1]

(18%)

[1]

[5](<10%)

[1]

[2](<10%)

[4](19%)

[5](7%)

Erythema multiforme

[1]

[1]

[1]

[10](17%)

[1]

Exanthems

[3](8%)

[3](21%)

[8]

[1]

(21%)

[1]

[3]

Exfoliative dermatitis

[1]

[3]

[1](14%)

[1]

[1](<10%)

[1](10%)

Facial edema

[1]

[2](<10%)

[1]

[2]

Fissures

[2](12%)

[1]

Folliculitis

[1]

[9](11%)

[4]

[1]

(<10%)

[3]

[4](49%)

Hand–foot syndrome

[2](10%)

[15](64%)

[14](50%)

[3](30–60%)

[2]

[3]

[8](76%)

(32%)

[2]

[97](89%)

[61](45–65%)

[3](36%)

Herpes

(<10%)

Hyperhidrosis

(<10%)

[1]

(<10%)

[1](12%)

Hyperkeratosis

(7%)

(7%)

[4]

Hypersensitivity

[2]

Hypomelanosis

[5]

[1]

Jaundice

(25%)

[1](35%)

[1]

?

Keratosis pilaris

[1]

[1]

[1]

Lesions

[1]

[2](38%)

?

Necrolysis

[1]

[1]

Necrosis

[1]

[1]

Nevi

[1]

[2]

[2]

Palmar–plantar hyperkeratosis

[1]

[1]

Panniculitis

[3]

[2]

Papulopustular eruption

[7](29%)

[3](21%)

[1]

?

Peripheral edema

[5](28%)

[3](44%)

[5](75%)

[2](37%)

[1](44%)

[1](17%)

Photosensitivity

[2]

[1]

[1](<10%)

[6](23%)

?

Phototoxicity

[1]

[2]

Pigmentation

[1]

[9](60%)

[1](18%)

[2]

[12](38%)

[4]

Pityriasis rubra pilaris

[1]

[1]

Pruritus

[2](13%)

[1](8%)

[3](14%)

[8](21%)

[4](61%)

[3](10%)

[3](33%)

[8](9–21%)

[1](19%)

[10](21%)

[3](<10%)

[2](11%)

Psoriasis

[2]

[1]

[1]

[2]

Purpura

[3]

[1]

[1]

Pyoderma gangrenosum

[1]

[4]

Radiation recall dermatitis

[1]

[3]

[1]

Rash

[43](92%)

[3](14%)

[1](30%)

[4](16%)

[9](34%)

[105](80%)

[59](66–85%)

[23](69%)

[24](55%)

(21%)

[10](56%)

[4](41%)

[47](30–75%)

[14](14–38%)

[32](67%)

✓✓

Rosacea

[2]

[1]

[1]

Seborrheic dermatitis

[1]

[1]

[1]

Skin reactions

[1]

[1]

Squamous cell carcinoma

[1]

[2]

[1]

[7]

Stevens–Johnson syndrome

[1]

[11]

[1]

[2]

Sweet’s syndrome

[1]

[1]

Telangiectasia

[1]

[1]

Toxic epidermal necrolysis

[1]

[1]

Toxicity

[2]

[2]

[6](36%)

[7](84%)

[9](68%)

[8](30–44%)

[6](46%)

[1]

[6]

[14](75%)

[20](67%)

[9](48–50%)

Ulcerations

[2]

[1]

Urticaria

(<10%)

[1]

[1]

(<10%)

Vasculitis

[1]

[1]

[1]

[1]

Wound complications

[1]

[1]

[1]

Xerosis

[6](15%)

(10%)

[1](23%)

(<10%)

[11](56%)

[11](53%)

[1](<10%)

[1](29%)

[1](20%)

[6](14%)

[3](17%)

[2](15%)

HAIR

Alopecia

[1](7%)

[2](6%)

(16%)

[1](<10%)

[10](14%)

[6]

[1](10–15%)

[2](33%)

(12%)

[2](<10%)

[2](71%)

[24](67%)

[3](5–12%)

[1]

Hair changes

(34%)

[3]

[1]

?

Hair pigmentation

[2](34%)

[2]

[1]

[7](38%)

?

Hypertrichosis

[4]

[2]

NAILS

Nail changes

[2](16%)

[2](17%)

[1](17%)

Nail disorder

[1](10%)

[1](<10%)

Nail pigmentation

[1]

[1]

Paronychia

[9](33–85%)

[11](15%)

[13](14–32%)

[3](27%)

[3](7%)

?

Pyogenic granuloma

[1]

[2]

Splinter hemorrhage

[3](70%)

[1]

[1]

?

Subungual hemorrhage

[1]

[3]

MUCOSAL

Aphthous stomatitis

[1]

[1]

(41%)

[1]

?

Cheilitis

[1](7%)

[1]

[1](14%)

[1]

Epistaxis

[3](17%)

[1](8%)

[1]

(12%)

[1]

[2](11%)

[2](13%)

Glossodynia

[1]

(25%)

(<10%)

[1](15%)

?

Mucocutaneous eruption

[1]

[1]

[1]

Mucosal inflammation

[6](69%)

[2](15%)

[2](23%)

[1](18%)

[1](15%)

[1](50%)

[4](54%)

[1](27%)

Mucositis

[10](50–90%)

[1]

[1](16%)

[9](21%)

[4](6–17%)

[2](15%)

[2](11–35%)

[12](28%)

[16](~60%)

[2](14%)

Oral mucositis

[1]

[1](33%)

[1](20%)

?

Oral ulceration

[1]

[1]

[3](15%)

(41%)

[1](5%)

?

Oropharyngeal pain

[1]

(25%)

[1](10%)

?

Rhinorrhea

(11%)

Stomatitis

[17](50–90%)

[1](15%)

(51%)

[1](11%)

[1]

[9](9–19%)

[7](6–17%)

[1](41%)

[2](41%)

[1]

[11](28%)

[15](60%)

[2](33%)

Xerostomia

[1](20%)

[1](33%)

[1](44%)

(17%)

[1](11%)

[1](<10%)

[2](~60%)

Aft Afatinib; Axt Axitinib; Cbo Cabozantinib; Crz Crizotinib; Dsa Dasatinib; Erl Erlotinib; Gft Gefitinib; Imt Imatinib; Lpt Lapatinib; Lnv Lenvatinib; Nlo Nilotinib; Nnt Nintedanib; Srf Sorafenib; Snt Sunitinib; Vnd Vandetanib 316 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362